TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery

NCT04197687 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

480

Enrollment

OTHER

Sponsor class

Conditions

Breast Adenocarcinoma
Stage II Breast Cancer AJCC v6 and v7
Stage IIA Breast Cancer AJCC v6 and v7
Stage IIB Breast Cancer AJCC v6 and v7
Stage III Breast Cancer AJCC v7
Stage IIIA Breast Cancer AJCC v7
Stage IIIB Breast Cancer AJCC v7
Stage IIIC Breast Cancer AJCC v7

Interventions

BIOLOGICAL: Multi-epitope HER2 Peptide Vaccine TPIV100
BIOLOGICAL: Pertuzumab
OTHER: Placebo Administration
BIOLOGICAL: Sargramostim
BIOLOGICAL: Trastuzumab
BIOLOGICAL: Trastuzumab Emtansine

Sponsor

Academic and Community Cancer Research United

Collaborators

[object Object]